Business Insider
My Markets Watchlist
Markets Stocks

AbCellera Biologics Inc Registered Shs Stock , ABCL

2.44 +0.08 +3.39%
03:59:59 PM EDT 6/6/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/06/2025 the closing price of the AbCellera Biologics Inc Registered Shs share was $2.36 on BTT. Compared to the opening price on Friday 06/06/2025 on BTT of $2.40, this is a drop of 1.69%. AbCellera Biologics Inc Registered Shs's market capitalization is $598.86 M by 298.48 M shares outstanding.

AbCellera Biologics Stock Snapshot

2.43
Bid
100.00
Bid Size
2.45
Ask
3,900.00
Ask Size
6/6/2025
Date
3:59 PM
Time
141,948.00
Volume
2.36
Prev. Close
2.40
Open
728.30 M
Market Cap in USD
298.48 M
Number of Shares
298.48 M
Total Number of Shares
2.39
Day Low
2.48
Day High
2.44
1.90
52 Week Low
3.88
52 Week High
2.44
0.00
Dividend in USD
0.00
Dividend Yield
75.03
Free Float in %
-0.55
EPS in USD
3.57
Book Value per Share in USD
-0.37
Cash Flow per Share in USD

Historical Prices for AbCellera Biologics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

AbCellera Biologics Analyst Data

Total Analysts: 5
Buy Ratings: 5 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 10.00 Median: 16.60 Highest: 24.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

AbCellera Biologics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
03/03/25 The Benchmark Company
Maintained Hold
02/28/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $10
02/22/24 The Benchmark Company
Upgraded to Buy
02/21/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $17
10/13/23 Piper Sandler
Maintained Buy $20
08/31/23 The Benchmark Company
Maintained Buy $12
08/04/23 Goldman Sachs
Maintained Buy $24

AbCellera Biologics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 26 52 78 144 204
Dividend - - - - -
Dividend Yield (in %) 0.00 % - - - -
EPS -0.62 -0.57 -0.59 -0.25 -0.09
P/E Ratio -3.91 -4.25 -4.14 -9.76 -27.11
EBIT -256 -248 -235 -195 -151
EBITDA -235 -240 -277 - -
Net Profit -199 -201 -207 -175 -138
Net Profit Adjusted -121 -112 -87 -50 3
Pre-Tax Profit -219 -210 -207 -175 -128
Pre-Tax Profit Reported -234 - - - -
EPS (Non-GAAP) ex. SOE -0.62 -0.57 -0.59 -0.25 -0.09
EPS (GAAP) -0.67 -0.61 -0.60 -0.50 -0.35
Gross Income 17 23 - - -
Cash Flow from Investing 111 113 - - -
Cash Flow from Operations 44 -136 - - -
Cash Flow from Financing - - - - -
Cash Flow per Share -0.30 - - - -
Free Cash Flow - - - - -
Free Cash Flow per Share - - - - -
Book Value per Share - - - - -
Net Debt 45 -6 -34 - -
Research & Development Exp. 173 184 199 208 217
Capital Expenditure - - - - -
Selling, General & Admin. Exp. 83 88 91 95 99
Shareholder’s Equity 917 737 - - -
Total Assets 1,271 1,105 - - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 9 9 8 8
Average Estimate - -0.141 USD -0.143 USD -0.624 USD -0.575 USD
Year Ago - -0.126 USD -0.173 USD -0.553 USD -
Publish Date - 8/12/2025 11/11/2025 - -
Revenue Estimates
No. of Analysts - 10 10 10 9
Average Estimate - 7 USD 7 USD 26 USD 52 USD
Year Ago - 7 USD 7 USD 29 USD -
Publish Date - 8/12/2025 11/11/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 28.83 38.03 485.42 375.20 233.16 11.61 8.83
Change of sales in % -24.17 -92.17 29.38 60.92 1,907.96 31.49 -
Gross profit on sales -68.17 7.13 - - - - -
Gross profit on sales change in % - - - - - - -
Operating income -314.77 -237.21 282.95 249.93 183.17 -4.12 -0.75
Operating income change in % -32.70 - 13.21 36.44 - -447.03 -
Income before tax -200.40 -174.03 239.10 219.15 157.83 -2.21 0.31
Income before tax change in % -15.15 - 9.10 38.85 - - -
Income after tax -162.86 -146.40 158.52 153.46 118.92 -2.21 0.31
Income after tax change in % -11.24 - 3.29 29.05 - - -

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 304.47 335.78 307.63 292.84 175.03 13.24 9.88
Long-term liabilities per share 0.26 0.42 0.66 0.61 0.27 0.03 0.02
Equity 1,056.08 1,152.32 1,233.28 1,025.73 830.51 10.25 11.61
Equity change in % -8.35 -6.56 20.23 23.51 30,587.98 -33.21 -
Balance sheet total 1,360.55 1,488.09 1,540.91 1,318.57 1,005.54 23.49 21.49
Balance sheet total change in % -8.57 -3.43 16.86 31.13 4,181.05 9.29 -

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 0.10 0.13 1.54 1.18 0.87 0.08 0.06
P/E ratio (year end quote, basic EPS) - - 18.22 25.70 91.19 - -
P/E ratio (year end quote, diluted EPS) - - 20.12 29.66 91.19 - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 - -
Equity ratio in % 77.62 77.44 80.04 77.79 82.59 43.65 54.02
Debt ratio in % 22.38 22.56 19.96 22.21 17.41 56.35 45.98

AbCellera Biologics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Thermopylae Holdings Ltd. 03/10/2025 343,631.00 56,143,640.00 2.16 Buy No
Montalbano John S. 03/09/2025 25,000.00 171,000.00 2.30 Buy No
Montalbano John S. 03/05/2025 60,000.00 146,000.00 2.34 Buy No
Thermopylae Holdings Ltd. 12/03/2024 286,000.00 55,800,009.00 n/a Sell No
Hansen Carl L. G. 11/24/2024 56,125.00 898,000.00 2.70 Buy No
Hansen Carl L. G. 09/19/2024 56,125.00 841,875.00 2.70 Buy No
Thermopylae Holdings Ltd. 08/28/2024 283,516.00 56,086,009.00 2.61 Buy No
Lecault Veronique 06/20/2024 83,334.00 2,123,456.00 0.19 Buy No
Hansen Carl L. G. 05/30/2024 56,125.00 785,750.00 2.70 Buy No
Hansen Carl L. G. 02/25/2024 56,125.00 729,625.00 2.70 Buy No
Thermopylae Holdings Ltd. 12/18/2023 210,000.00 55,802,493.00 n/a Sell No
Hansen Carl L. G. 11/22/2023 56,125.00 673,500.00 2.70 Buy No
Montalbano John S. 11/07/2023 10,000.00 86,000.00 4.46 Buy No
Montalbano John S. 11/05/2023 20,000.00 76,000.00 4.64 Buy No
Hayden Michael R 09/21/2023 20,000.00 1,323,397.00 4.91 Buy No
Lecault Veronique 09/11/2023 20,000.00 2,040,122.00 5.19 Buy No
Hansen Carl L. G. 08/23/2023 56,125.00 617,375.00 2.70 Buy No
Hayden Michael R 08/07/2023 30,000.00 1,303,397.00 5.90 Buy No
Hansen Carl L. G. 05/25/2023 56,125.00 561,250.00 2.70 Buy No
Booth Andrew 05/25/2023 14,500.00 153,000.00 6.85 Buy No
Thermopylae Holdings Ltd. 05/25/2023 153,000.00 56,012,493.00 6.52 Buy No
Lecault Veronique 05/04/2023 250,000.00 2,020,122.00 0.19 Buy No
Hansen Carl L. G. 02/21/2023 56,125.00 505,125.00 2.70 Buy No
Booth Andrew 12/19/2022 50,000.00 138,500.00 n/a Sell No
Booth Andrew 12/19/2022 50,000.00 188,500.00 0.19 Buy No

AbCellera Biologics Dividend Calendar

Date Name Dividend *yield Currency
2024 AbCellera Biologics Inc Registered Shs 0.00 0.00 USD
2023 AbCellera Biologics Inc Registered Shs 0.00 0.00 USD
2022 AbCellera Biologics Inc Registered Shs 0.00 0.00 USD
2021 AbCellera Biologics Inc Registered Shs 0.00 0.00 USD
2020 AbCellera Biologics Inc Registered Shs 0.00 0.00 USD
2019 AbCellera Biologics Inc Registered Shs - - USD
2018 AbCellera Biologics Inc Registered Shs - - USD
*Yield of the Respective Date

AbCellera Biologics Calendar

Event Estimate Info Date
Annual General Meeting -0.550 USD Annual General Meeting 06/12/2025
Earnings Report -0.142 USD Q2 2025 Earnings Release 08/12/2025
Earnings Report -0.143 USD Q3 2025 Earnings Release 11/11/2025
Earnings Report -0.146 USD Q4 2025 Earnings Release 02/24/2026
Earnings Report -0.114 USD Q1 2026 Earnings Release 05/07/2026

AbCellera Biologics Past Events

Event Actual EPS Info Date
Earnings Report -0.150 USD Q1 2025 Earnings Release 05/08/2025
Earnings Report -0.120 USD Q4 2024 Earnings Release 02/27/2025
Earnings Report -0.170 USD Q3 2024 Earnings Release 11/04/2024
Earnings Report -0.130 USD Q2 2024 Earnings Release 08/06/2024
Annual General Meeting -0.510 USD Annual General Meeting 06/13/2024
Earnings Report -0.140 USD Q1 2024 Earnings Release 05/07/2024
Earnings Report -0.170 USD Q4 2023 Earnings Release 02/20/2024
Earnings Report -0.100 USD Q3 2023 Earnings Release 11/02/2023
Earnings Report -0.110 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting 0.560 USD Annual General Meeting 06/15/2023
Earnings Report -0.140 USD Q1 2023 Earnings Release 05/04/2023
Earnings Report -0.100 USD Q4 2022 Earnings Release 02/21/2023
Earnings Report 0.090 USD Q3 2022 Earnings Release 11/08/2022
Earnings Report -0.020 USD Q2 2022 Earnings Release 08/09/2022
Annual General Meeting 0.560 USD Annual General Meeting 06/15/2022
Earnings Report 0.590 USD Q1 2022 Earnings Release 05/10/2022
Earnings Report 0.220 USD Q4 2021 Earnings Release 02/24/2022

AbCellera Biologics Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
OSZAR »